Corporate development teams rely on investment bankers and accounting and consulting firms for M&A (mergers and acquisitions) due diligence. Those advisors cover financial modeling, market sizing, deal structure and compliance well. Clinical and device-engineering questions often call for a different kind of reader: someone who can judge whether physicians will change practice to use a device, whether the evidence supports the adoption an acquisition model assumes, and whether the product can be made at the volume and cost the plan requires.
This article describes three risk categories where a clinical and engineering read adds the most, and how a second opinion can sit alongside existing advisors.
A Composition Gap, Not a Competence Gap
A regulatory specialist can confirm that a submission was complete and that a clearance or approval is in place. Whether physicians will adopt the device, whether the clinical workflow change is realistic, and whether the evidence supports the adoption rate in the model are clinical judgments. Whether the design is ready for volume production is an engineering one. The question for a deal team is whether anyone on the diligence team is trained to make those calls.
Three Risk Categories That Need a Clinical and Engineering Read
1. Physician Adoption: Authorization Is Not Adoption
A device can be cleared, supported by clinical data and reimbursed, and still see slow uptake if physicians will not change how they work. Adoption barriers include equipment integration, added procedure time, training demands and existing supplier relationships; see our article on the clinical adoption gap.
Market research tends to ask how many target physicians know about a device and how large the market is, which is less suited to surfacing workflow friction. As a physician, I have seen devices that looked compelling on paper struggle in practice because of procedural friction, a learning curve or poor integration with existing systems. Diligence that includes direct conversations with target users about how they would actually use the device, and what would have to change for them to adopt it, can surface friction that market research misses.
2. Reimbursement Durability: Payment Policy Can Change Quickly
Medicare payment policy can reset a product category's economics in a single rule. Under the CY 2026 Physician Fee Schedule final rule, announced October 31, 2025, CMS began paying most skin substitutes as incident-to supplies at an initial rate of about $127 per square centimeter; see our skin substitute case study. Policy moves in the other direction too: for 2026, Medicare began paying new remote patient monitoring codes for shorter monitoring periods (CPT 99445) and shorter management time (CPT 99470), as our RPM article describes.
A historical view, such as how long Medicare has paid a code at a given rate, does not show whether that payment is durable. More useful questions are whether current payment is consistent with the evidence, whether pending rules or coverage reviews touch the category, and whether changes in adjacent categories could reach the product; see our reimbursement red flags.
3. Manufacturing Scale: From Prototype to Production
A device that performs well at prototype volumes faces different problems at commercial scale: components that are easy to source in small quantities but constrained at volume, quality variation when production expands to more lines or sites, cost-of-goods assumptions that depend on manufacturing improvements not yet validated, and facilities that need capital to expand.
Supply-chain reviews ask whether the contract manufacturer is capable and whether there is single-source supplier risk. Engineering diligence also asks whether the design itself is ready for volume production, and whether the cost reductions in the model depend on design or process changes that have not been validated; see our manufacturing due diligence questions.
The Second-Opinion Model
In a second-opinion approach, bankers and accounting or consulting firms carry out financial and strategic diligence, and a clinical and engineering team reviews regulatory status, clinical evidence, manufacturing maturity and adoption risk in parallel. It adds to existing advisory work rather than replacing it.
Vantage's version is the M&A Report ($25,000, within 48 hours of a complete intake): diligence reviewed by a physician (Arvind Ravinutala, MD) and a biomedical engineer (Aswini Ravinutala, BME), with each factual claim cited to its source, plus integration risk and reference-contact review and a 60-minute strategy session.
Different Expertise, Different Questions
Financial and strategic advisors: financial modeling, market sizing, regulatory compliance verification and reimbursement pathway confirmation.
Clinical and engineering second opinion: physician adoption, manufacturing maturity, regulatory pathway realism and clinical evidence gaps. Not a substitute for financial modeling, which is why the bankers stay.
Together: a fuller picture before the acquisition decision.
The Bottom Line
Corporate acquirers bring strong financial and strategic diligence. Clinical and device-engineering risk calls for a different kind of reader, and a focused second opinion running alongside existing advisors is one way to get that read before close. We do not predict how an acquisition will perform; we assemble what the record shows so the deal team can decide what warrants further discovery.
References
Evaluating a Transaction?
Vantage provides clinical and technical second opinions for corporate M&A and PE-backed acquisitions. If you have an active deal or portfolio company that warrants deeper clinical diligence, we should talk.